Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Research & Development In Brief

This article was originally published in The Tan Sheet

Executive Summary

Nestle eyes infant probiotic products: Nestle Nutrition is looking to launch probiotic-containing infant nutrition products targeting upper respiratory tract infections, according to an agreement announced March 28. New Zealand biotech firm BLIS Technologies has agreed to work exclusively with the Nestle SA division to carry out the research and development of probiotics "suitable for incorporation into infant nutrition products," the company says. "If the project proceeds according to plan, the company will commit significant resources to the development over the next three years," BLIS says. The probiotic helps provide protection against Streptococcus pyogenes, BLIS says, adding that the agreement should enable it to "build a platform of probiotics with significant market opportunities." This is not Nestle's first foray into infant probiotics (1"The Tan Sheet" Jan. 29, 2007, In Brief)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100414

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel